6533b86efe1ef96bd12cc895
RESEARCH PRODUCT
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma
Alessandra RomanoMarco SantoroGiovanni MartinelliSergio SiragusaClaudio CerchioneFrancesco Di RaimondoConcetta Conticellosubject
Oncologymedicine.medical_specialtyTime FactorsDisease030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineChromosome instabilityAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorsLenalidomideMultiple myelomaLenalidomide030219 obstetrics & reproductive medicinebusiness.industryGeneral Medicinemedicine.diseaseResponse to treatmentProgression-Free SurvivalPost transplantConsolidation Chemotherapymedicine.anatomical_structureProteasomeBone marrowMultiple MyelomabusinessProteasome InhibitorsStem Cell Transplantationmedicine.drugdescription
Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-01 | Panminerva Medica |